Extrait

This phase I trial studies the side effects and best dose of veliparib when given together with liposomal irinotecan in treating patients with solid tumors. Liposomal irinotecan and veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Critère d'inclusion

• Malignant Solid Neoplasm

Liens

• nct
• ictrp